Please login to the form below

Not currently logged in
Email:
Password:

CC-486

This page shows the latest CC-486 news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

We now look forward to taking the next steps to bring CC-486 to eligible AML patients in need,” he added. ... According to a statement issued by BMS, regulatory submissions for CC-486 are planned for the first half of 2020.

Latest news

  • Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

    The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... The new  QUAZAR AML-001 study compared CC-486 to placebo as a maintenance therapy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...

Infographics